19:37 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a tool...
23:15 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Sihuan launches U.S. unit

Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:460) established a global business development unit in the U.S., through which it is seeking to expand and speed its international projects. The unit will be led by CBO Frank...
18:22 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting β-catenin in combination with Xtandi enzalutamide could help treat prostate cancer. In tumor samples from prostate cancer patients, levels of β-catenin were higher in...
23:00 , Oct 19, 2017 |  BC Extra  |  Company News

Management tracks: Neurocrine, Cellect, Marina

Neurology and endocrine company Neurocrine Biosciences Inc. (NASDAQ:NBIX) said President, COO and Interim CFO David-Alexander Gros is stepping down. CEO Kevin Gorman will serve as interim CFO while the company seeks a replacement. Stem cell production...
23:54 , Feb 24, 2017 |  BC Extra  |  Company News

Management Tracks

Celgene Corp. (NASDAQ:CELG) said President and COO Jacqualyn Fouse will retire on June 30. Scott Smith will succeed Fouse effective April 1. He is president of global inflammation and immunology. Terrie Curran will be promoted...
20:44 , Feb 10, 2017 |  BC Week In Review  |  Company News

Marina Biotech, LipoMedics deal

Marina granted LipoMedics rights to Marina's SMARTICLES liposomal-based delivery technology to deliver nanoparticles, including small molecules, peptides, proteins and biologics. Marina is eligible for up to $90 million in milestones. LipoMedics could not be reached,...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

MRX34: Phase I discontinued

Mirna voluntarily terminated an open-label, dose-escalation, dose-expansion, U.S. and Korean Phase I trial of IV MRX34 after a fifth, immune-related serious adverse event was reported in patients who received the compound. The company said the...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

PNT2258: Interim Phase II data

Interim data from 37 patients with relapsed or refractory DLBCL in the open-label, U.S. and Puerto Rican Phase II Wolverine trial showed that once-daily 120 mg/m 2 IV PNT2258 on days 1-5 of each 21-day...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting Wnt/CTNNB1 signaling could help treat nodular fasciitis, alveolar rhabdomyosarcoma and other USP6-overexpressing cancers. Screening of siRNA libraries in HEK cells and a human sarcoma cell line identified...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Company News

Marina Biotech, Microlin Bio deal

Microlin will acquire “substantially all” of Marina’s assets for $1 million in cash and 6.7 million shares valued at $10.1 million based on Microlin’s close of $1.50 before the deal was announced. The deal includes...